Licensed by Pfizer Catalog No.S2133
Molecular Weight(MW): 171.24
Gabapentin is a GABA analogue, used to treat seizures and neuropathic pain.
Purity & Quality Control
Choose Selective GABA Receptor Inhibitors
|Description||Gabapentin is a GABA analogue, used to treat seizures and neuropathic pain.|
Gabapentin produces concentration-dependent inhibitions of the K(+)-induced [Ca(2+)](i) increase in fura-2-loaded human neocortical synaptosomes with IC50 of 17 mM and maximal inhibition of 37%. Gabapentin may bind to the Ca(2+) channel alpha 2 delta subunit to selectively attenuate depolarization-induced Ca(2+) influx of presynaptic P/Q-type Ca(2+) channels; this results in decreased glutamate/aspartate release from excitatory amino acid nerve terminals leading to a reduced activation of AMPA heteroreceptors on noradrenergic nerve terminals.  Gabapentin produces alterations in the cytosolic and extracellular concentrations of several amino acids, including L-leucine, L-valine and L-phenylalanine, in rat cortical astrocytes and synaptosomes, effects that are postulated to be of pharmacological significance. Gabapentin reduces potassium-evoked calcium influx via voltage-gated calcium channels in a mouse pituitary cell line that constitutively expresses GABAB receptors comprising the functional gb1a–gb2 subunit heterodimer. Gabapentin can increase N-methyl-d-aspartate (NMDA)-evoked currents in GABA-positive rat dorsal horn neurones in the presence of protein kinase C, possibly by increasing the glycine sensitivity of the NMDA receptor complex. Gabapentin produces a delayed allosteric enhancement of an unspecified voltage-activated potassium current in rat dorsal root ganglion neurons. 
|In vivo||Gabapentin dose-dependently (10-100 mg/kg, p.o.) blocks both static and dynamic allodynia in the rats. |
|In vitro||Water||34 mg/mL (198.55 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02160301||Suspended||Post Operative Pain Control||University of North Carolina, Chapel Hill||November 2017||Phase 4|
|NCT03053427||Not yet recruiting||Restless Legs Syndrome (RLS)||Astellas Pharma Inc||March 2017||Phase 4|
|NCT03012815||Not yet recruiting||Alcohol Withdrawal Syndrome||Mayo Clinic||March 2017||Phase 4|
|NCT02957097||Not yet recruiting||Pain, Postoperative|Acute Pain|Facial Pain||Massachusetts General Hospital||February 2017||Phase 4|
|NCT02999724||Recruiting||Pelvic Organ Prolapse||Mount Sinai Hospital, Canada||January 2017||Phase 3|
|NCT02987985||Not yet recruiting||Anesthesia|General Anesthesia|Analgesics, Opioid|Postoperative Complications|Pathologic Processes|Physiologic Effects of Drugs|Narcotics|Analgesics|Sleep Disordered Breathing|Obstructive Sleep Apnea of Child|Tonsillectomy|Respiratory Depression|Dexmedetomidine|Ketamine|Lidocaine|Gabapentin|Pulse Oximetry||University of Saskatchewan||January 2017||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.